ZN-d5

N/A

Report date: 2023/06/08 20:00:28
NME

Base Information

Drug NameZN-d5
Drug Alias NameZN-d5
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsAmyloidosisImmunoglobulin Light-chain AmyloidosisLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesKalyra Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesZeno Pharmaceuticals IncK-GROUP ALPHA Inc
Inactive CompaniesPatheon Development Services IncZhengtengkang Biotechnology (Shanghai) Co LtdZentera Therapeutics HK Ltd
Active IndicationsAmyloidosisImmunoglobulin Light-chain AmyloidosisLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A